Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Maria V. Deligiorgi & Dimitrios T. Trafalis. (2021) The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. Expert Opinion on Drug Safety 20:2, pages 191-213.
Read now
Read now
Emanuela Dell’Aquila, Grazia Armento, Michele Iuliani, Sonia Simonetti, Loretta D’Onofrio, Tea Zeppola, Cristina Madaudo, Marco Russano, Fabrizio Citarella, Giulia Ribelli, Francesco Pantano, Bruno Vincenzi, Giuseppe Tonini & Daniele Santini. (2020) Denosumab for cancer-related bone loss. Expert Opinion on Biological Therapy 20:11, pages 1261-1274.
Read now
Read now
Maria V. Deligiorgi & Dimitrios T. Trafalis. (2020) Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective. Expert Opinion on Biological Therapy 20:11, pages 1331-1346.
Read now
Read now
A. Ludwig Meiss, Florian Barvencik, Kornelia Babin & Gerald Eggers-Stroeder. (2017) Denosumab and surgery for the treatment of Perthes’ disease in a 9-year-old boy: favorable course documented by comprehensive imaging— a case report. Acta Orthopaedica 88:3, pages 354-357.
Read now
Read now
Daniel C Austin, Michael T Torchia, Christian M Klare & Robert V Cantu. (2017) Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthopaedica 88:3, pages 351-353.
Read now
Read now
Laura López-Delgado, Leyre Riancho-Zarrabeitia & José A. Riancho. (2016) Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 389-398.
Read now
Read now
. (2014) Addendum in print. Acta Orthopaedica 85:1, pages 2-2.
Read now
Read now
Articles from other publishers (47)
Yao Xiao, Yiqian Chen, Yan Huang & Yuan Xiao. (2023) Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Scientific Reports 13:1.
Crossref
Crossref
Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Yuki Funauchi, Takashi Hirai, Masato Yuasa, Yu Matsukura, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake & Atsushi Okawa. (2023) Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study. JBMR Plus 7:7.
Crossref
Crossref
Willem H. Schreuder, Astrid Lipplaa, Arjen H.G. Cleven, Henk van den Berg, Peter H. Bisschop, Renate T. de Jongh, Max J.H. Witjes, Peter A.W.H. Kessler, Matthias A.W. Merkx, Esther Edelenbos, Cornelis Klop, Ruud Schreurs, Anneke M. Westermann, Jacqueline M. Tromp, Henriette Levenga, Hans Gelderblom & Jan de Lange. (2022) RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis. European Journal of Cancer 175, pages 263-273.
Crossref
Crossref
Judith Everts‐Graber, Harald Bonel, Daniel Lehmann, Brigitta Gahl, HansJörg Häuselmann, Ueli Studer, Hans‐Rudolf Ziswiler, Stephan Reichenbach & Thomas Lehmann. (2022) Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study. JBMR Plus 6:10.
Crossref
Crossref
Yuta Tsukagoshi & Yuki Matsushita. (2022) Bone regeneration: A message from clinical medicine and basic science. Clinical Anatomy 35:6, pages 808-819.
Crossref
Crossref
A. Strobbe, D. Slock & B. Maeyaert. (2022) Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus. Tijdschrift voor Geneeskunde.
Crossref
Crossref
A. Strobbe, D. Slock & B. Maeyaert. (2022) Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Jeremy Keng Meng Goh, Joyce Suang Bee Koh, Alvin Choong Meng Ng, Meng Ai Png & Tet Sen Howe. (2022) Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report. Calcified Tissue International 111:1, pages 96-101.
Crossref
Crossref
Dennis M. Black, Katherine Condra, Annette L. Adams & Richard Eastell. (2022) Bisphosphonates and the risk of atypical femur fractures. Bone 156, pages 116297.
Crossref
Crossref
Shinya Toriumi, Akinobu Kobayashi, Hitoshi Sueki, Munehiro Yamamoto & Yoshihiro Uesawa. (2021) Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database. Pharmaceuticals 14:12, pages 1299.
Crossref
Crossref
H. E. Skibicki, D. Y. Ponzio, J. A. Brustein, Z. D. Post, A. C. Ong & F. R. Orozco. (2021) A cautionary case: osteoporotic femur fracture after robotic-assisted total knee arthroplasty. Osteoporosis International 32:10, pages 2125-2129.
Crossref
Crossref
Lanny V. Griffin, Elizabeth Warner, Saroj Palnitkar, Shijing Qiu, Mahalakshmi Honasoge, Shawna G. Griffin, George Divine & Sudhaker D. Rao. (2021) Bone Nanomechanical Properties and Relationship to Bone Turnover and Architecture in Patients With Atypical Femur Fractures: A Prospective Nested Case‐Control Study. JBMR Plus 5:9.
Crossref
Crossref
Yusuke Fuchioka, Kohji Suzuki, Hiroaki Kimura, Hideto Furuoka & Yuri Tamura. (2021) Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents. Journal of Rural Medicine 16:3, pages 170-173.
Crossref
Crossref
Michael R. McClung. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1737
1755
.
H. I. Piponov, J. M. Goldstein & G. M. Eisenberg. (2020) Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis—a case report. Osteoporosis International 31:11, pages 2263-2267.
Crossref
Crossref
Merav Bar, Susan M. Ott, E. Michael Lewiecki, Kyriakie Sarafoglou, Joy Y. Wu, Matthew J. Thompson, Jonathan J. Vaux, David R. Dean, Kenneth G. Saag, Shahrukh K. Hashmi, Yoshihiro Inamoto, Bhagirathbhai R. Dholaria, Mohamed A. Kharfan-Dabaja, Arnon Nagler, Cesar Rodriguez, Betty K. Hamilton, Nina Shah, Mary E.D. Flowers, Bipin N. Savani & Paul A. Carpenter. (2020) Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation 26:10, pages 1784-1802.
Crossref
Crossref
Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Takashi Hirai, Masato Yuasa, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake & Atsushi Okawa. (2020) Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report. Journal of Bone Oncology 23, pages 100301.
Crossref
Crossref
Denise M van de Laarschot, Malachi J McKenna, Bo Abrahamsen, Bente Langdahl, Martine Cohen-Solal, Núria Guañabens, Richard Eastell, Stuart H Ralston & M Carola Zillikens. (2020) Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. The Journal of Clinical Endocrinology & Metabolism 105:5, pages 1682-1699.
Crossref
Crossref
J. Brett Goodloe, Sarah Toner, Alyssa Althoff, Leah Herzog, Stacey Rothwell & Kristoff Reid. (2020) Bilateral Atypical Femur Fractures Complicated by Carbon Fiber Cephalomedullary Nail Fracture. JBJS Case Connector 10:3, pages e20.00182-e20.00182.
Crossref
Crossref
E. Michael Lewiecki. 2020. Osteoporosis. Osteoporosis
309
322
.
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi & Toshimi Takano. (2019) Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer 19:1.
Crossref
Crossref
Juan Tan, Hiroshige Sano & Kenneth Poole. (2019) Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. BMJ Case Reports 12:7, pages e229366.
Crossref
Crossref
E. Michael Lewiecki. (2018) New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Therapeutic Advances in Musculoskeletal Disease 10:11, pages 209-223.
Crossref
Crossref
Aline Granja Costa, E. Michael Lewiecki & John P. Bilezikian. 2018. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
553
558
.
Manish G. Agarwal, Manit K. Gundavda, Rajat Gupta & Rajeev Reddy. (2018) Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience. Clinical Orthopaedics & Related Research 476:9, pages 1773-1782.
Crossref
Crossref
Yuval Zur, Lior Rosenfeld, Chen Anna Keshelman, Nofar Dalal, Gali Guterman-Ram, Ayelet Orenbuch, Yulia Einav, Noam Levaot & Niv Papo. (2018) A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy. PLOS Biology 16:8, pages e2002979.
Crossref
Crossref
Tsutomu SugiharaMitsuru KoizumiKeiko HayakawaYoshinori ItoNaohiro Sata. (2018) Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab. Clinical Nuclear Medicine 43:5, pages 365-366.
Crossref
Crossref
Mohammad Al-Ashqar, Michalis Panteli, Gautam Chakrabarty & Peter V. Giannoudis. (2018) Atypical fractures: An issue of concern or a myth?. Injury 49:3, pages 649-655.
Crossref
Crossref
Kenneth Pittman, Yoland C Antill, Amanda Goldrick, Jeffrey Goh & Richard H de Boer. (2017) Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia-Pacific Journal of Clinical Oncology 13:4, pages 266-276.
Crossref
Crossref
David A. Hanley, Michael R. McClung, K. Shawn Davison, Larry Dian, Steve T. Harris, Paul D. Miller, E. Michael Lewiecki & David L. Kendler. (2017) Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. The American Journal of Medicine 130:7, pages 862.e1-862.e7.
Crossref
Crossref
Samantha Peiling Yang, Tae Won B. Kim, Patrick J. Boland & Azeez Farooki. (2017) Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. The Oncologist 22:4, pages 438-444.
Crossref
Crossref
Ammar Ismail, Amira Hassan Bekhet, Abdelrahman Ibrahim Abushouk, Sahar Mirbaha & Alireza Baratloo. (2017) Denosumab and Atypical Femoral Fractures: A Scoping Literature Review. Trauma Monthly 23:1.
Crossref
Crossref
A.R.B. Silva & V.L. Szejnfeld. (2017) FRATURA DIAFISÁRIA DE FÊMUR APÓS TROCA DE RISEDRONATO PARA DENOSUMABE: FRATURA ATÍPICA POR DENOSUMABE OU EFEITO RESIDUAL DO BISFOSFONATO?. Revista Brasileira de Reumatologia 57, pages S74.
Crossref
Crossref
Czar Louie Gaston, Robert J. Grimer, Michael Parry, Silvia Stacchiotti, Angelo Paolo Dei Tos, Hans Gelderblom, Stefano Ferrari, Giacomo G. Baldi, Robin L. Jones, Sant Chawla, Paolo Casali, Axel LeCesne, Jean-Yves Blay, Sander P. D. Dijkstra, David M. Thomas & Piotr Rutkowski. (2016) Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical Sarcoma Research 6:1.
Crossref
Crossref
Giuseppe Toro, Cristina Ojeda-Thies, Giampiero Calabrò, Gabriella Toro, Antimo Moretti, Guillermo Martínez-Díaz Guerra, Pedro Caba-Doussoux & Giovanni Iolascon. (2016) Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Olof Sköldenberg, Agata Rysinska, Thomas Eisler, Mats Salemyr, Henrik Bodén & Olle Muren. (2016) Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Leqin Xu, Jian Luo, Rongrong Jin, Zhiying Yue, Peng Sun, Zhengfeng Yang, Xinghai Yang, Wei Wan, Jishen Zhang, Shichang Li, Mingyao Liu & Jianru Xiao. (2016) Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption. Molecular Cancer Therapeutics 15:5, pages 854-865.
Crossref
Crossref
J. Selga, J. H. Nuñez, J. Minguell, M. Lalanza & M. Garrido. (2015) Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporosis International 27:2, pages 827-832.
Crossref
Crossref
Muneaki Ishijima, Yoshitomo Saita, Haruka Kaneko, Mayuko Kinoshita & Kazuo Kaneko. 2016. Osteoporosis in Orthopedics. Osteoporosis in Orthopedics
103
134
.
Z. Deniz Olgun, Arianna Gianakos, Jonathan E. Jo & Joseph M. Lane. 2016. Metastatic Bone Disease. Metastatic Bone Disease
121
129
.
Robert A Adler, Ghada El-Hajj Fuleihan, Douglas C Bauer, Pauline M Camacho, Bart L Clarke, Gregory A Clines, Juliet E Compston, Matthew T Drake, Beatrice J Edwards, Murray J Favus, Susan L Greenspan, Ross McKinneyJrJr, Robert J Pignolo & Deborah E Sellmeyer. (2016) Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 31:1, pages 16-35.
Crossref
Crossref
Sian Yik Lim, Naina Rastalsky, Edwin Choy & Marcy B. Bolster. (2015) Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone. Bone 81, pages 31-35.
Crossref
Crossref
Aline G. Costa & John P. Bilezikian. (2015) How Long to Treat with Denosumab. Current Osteoporosis Reports 13:6, pages 415-420.
Crossref
Crossref
Isabel Pérez-Núñez, José L. Pérez-Castrillón, María T. Zarrabeitia, Carmen García-Ibarbia, Laura Martínez-Calvo, José M. Olmos, Laisa S. Briongos, Javier Riancho, Victoria Camarero, Josep M. Muñoz Vives, Raquel Cruz & José A. Riancho. (2015) Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. Molecular and Cellular Biochemistry 409:1-2, pages 45-50.
Crossref
Crossref
Kareeann Sok Fun Khow & Tuck Yean Yong. (2014) Atypical femoral fracture in a patient treated with denosumab. Journal of Bone and Mineral Metabolism 33:3, pages 355-358.
Crossref
Crossref
Deniz Olgun, Arianna L. Gianakos, Jonathan Jo, Libi Galmer & Joseph M. Lane. 2015. Diagnosis and Management of Hip Disease. Diagnosis and Management of Hip Disease
141
158
.
. (2014) Denosumab. Reactions Weekly 1494:1, pages 20-20.
Crossref
Crossref